MLL白血病におけるグリコゲン合成キナーゼ3の維持と標的療法
Zhong Wang1, Kevin S Smith, Mark Murphy
1Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA.
Nature
|September 23, 2008
まとめ
グリコゲン合成キナーゼ3 (GSK3) は,p27を不安定化することによって,驚くほどMLL白血病の進行を促します. GSK3を阻害することは,この攻撃的な白血病サブタイプに対する新しいがん薬戦略として有望であることが示されています.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- バイオケミストリー バイオケミストリー
背景:
- グリコゲン合成キナーゼ3 (GSK3) は,様々なシグナル伝達経路における重要なキナーゼである.
- ガンにおけるGSK3の役割は不明であり,悪性腫瘍を標的とする強力な根拠はない.
- GSK3を含む特定の経路は,疾患の病原化に関与しており,GSK3阻害剤への関心を高めています.
研究 の 目的:
- MLL変異型ヒト白血病におけるGSK3の役割を調査する.
- GSK3阻害がMLL白血病の有効な治療戦略であるかどうかを判断する.
- GSK3がMLL白血病細胞の増殖を支えるメカニズムを解明する.
主な方法:
- GSK3.3の薬理学的抑制
- GSK3の活性に関する生理学的研究.
- MLL白血病モデルにおける遺伝子解析.
- p27 (Kip1) レベルと細胞増殖の評価
主要な成果:
- GSK3は,MLL変異性白血病細胞の増殖と生存に不可欠です.
- GSK3の阻害により,白血病細胞の増殖と変容が低下しました.
- GSK3は,MLL白血病におけるサイクリン依存キナーゼ阻害剤p27 (Kip1) を不安定化する.
- 臨床前のネズミモデルでは,GSK3抑制に対する有効性が示されました.
結論:
- GSK3は逆説的にMLL変異性白血病の腫瘍遺伝子として作用します.
- GSK3をターゲットにすることは,予後が悪いMLL白血病の有望な治療戦略です.
- GSK3阻害は,特定のヒト白血病の治療に新しいアプローチを提供します.
さらに関連する動画
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
19.0K
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
959
関連する概念動画
Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
